{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:30Z","timestamp":1740107730204,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10067-019-04669-0","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T05:12:17Z","timestamp":1563858737000},"page":"2957-2958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata"],"prefix":"10.1007","volume":"38","author":[{"given":"Kabir","family":"Sardana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-5365","authenticated-orcid":false,"given":"Aastha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pulin Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"issue":"7","key":"4669_CR1","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s10067-019-04577-3","volume":"38","author":"Greg Koller","year":"2019","unstructured":"Koller G, Cusnir I, Hall J, Ye C ( 2019 ) Reversible alopecia areata: a little known side effect of leflunomide. Clin Rheumatol. 38(7):2015\u20132016. doi: \n                    https:\/\/doi.org\/10.1007\/s10067-019-04577-3\n                    \n                  . [Epub ahead of print]","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"4669_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2165\/00002018-199410040-00005","volume":"10","author":"A Tosti","year":"1994","unstructured":"Tosti A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F (1994) Drug-induced hair loss and hair growth. Drug Saf 10(4):310\u2013317","journal-title":"Drug Saf"},{"issue":"1","key":"4669_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","volume":"5","author":"K Flanagan","year":"2019","unstructured":"Flanagan K, Sperling L, Lin J (2019) Drug-induced alopecia after dupilumab therapy. JAAD Case Rep 5(1):54\u201356","journal-title":"JAAD Case Rep"},{"issue":"8","key":"4669_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jdcr.2018.05.022","volume":"4","author":"M Lakhmiri","year":"2018","unstructured":"Lakhmiri M, Cavelier-Balloy B, Lacoste C, Cassius C, Baroudjian B, Delyon J, Lebb\u00e9 C, Reygagne P (2018) Nivolumab-induced alopecia areata: a reversible factor of good prognosis? JAAD Case Rep 4(8):761\u2013765","journal-title":"JAAD Case Rep"},{"issue":"6","key":"4669_CR5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jaad.2014.03.005","volume":"70","author":"M Tauber","year":"2014","unstructured":"Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, Cohen JD, Coquerelle P, Goujon E, Jullien D, Brixi H (2014) Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70(6):1146\u20131149","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4669_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1590\/abd1806-4841.20142869","volume":"89","author":"M Hammerschmidt","year":"2014","unstructured":"Hammerschmidt M, Mulinari Brenner F (2014) Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol 89(5):729\u2013734","journal-title":"An Bras Dermatol"},{"key":"4669_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/pde.13688","volume":"35","author":"K Sardana","year":"2018","unstructured":"Sardana K, Gupta A, Gautam RK (2018) Recalcitrant alopecia areata responsive to leflunomide and anthralin\u2014potentially undiscovered JAK\/STAT inhibitors? Pediatr Dermatol 35:856\u2013858","journal-title":"Pediatr Dermatol"},{"key":"4669_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043\u20131049","journal-title":"Nat Med"},{"key":"4669_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/ard.2003.014738","volume":"63","author":"MC Kraan","year":"2004","unstructured":"Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP (2004) Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 63:1056\u20131061","journal-title":"Ann Rheum Dis"},{"key":"4669_CR10","first-page":"3079","volume":"28","author":"WW Cao","year":"1996","unstructured":"Cao WW, Kao PN, Aoki Y, Xu JC, Shorthouse RA, Morris RE (1996) A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 28:3079\u20133080","journal-title":"Transplant Proc"},{"key":"4669_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","volume":"8","author":"YD Fragoso","year":"2015","unstructured":"Fragoso YD, Brooks JB (2015) Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 8:315\u2013320","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4669_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0167-4889(89)90088-8","volume":"1012","author":"Y Marijnen","year":"1989","unstructured":"Marijnen Y, de Korte D, Haverkort W et al (1989) Studies on the incorporation of precursors into purine and pyrimidine nucleotides via \u201cde novo\u201d and \u201csalvage\u201d pathways in normal lymphocytes and lymphoblastic cell-line cells. Biochim Biophys Acta 1012:148\u2013155","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"4669_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1523-1747.1999.00571.x","volume":"112","author":"KJ McElwee","year":"1999","unstructured":"McElwee KJ (1999) Third international research workshop on alopecia Areata. J Invest Dermatol 112(5):822\u2013824","journal-title":"J Invest Dermatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04669-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04669-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04669-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:27:41Z","timestamp":1595374061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04669-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4669"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04669-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}